SAN FRANCISCO, USA, April 25, 2024/PRNewswire/ -- Cinda Biopharmaceutical Group (HKEx stock code: 01801), a biopharmaceutical company dedicated to the development, production and sale of innovative drugs for major diseases such as oncology, autoimmunity, metabolism, cardiovascular, ophthalmology, etc., announced today that it will release about 20 new clinical research data at the 2024 American Society of Clinical Oncology (ASCO) annual meeting, including the company's series of monoclonal antibodies, double antibodies and antibody-conjugated drugs (ADC) in development pipeline, and Dabershu(Cindilizumab injection), NellickInnovative oncology drugs such as (orebatinib) and taretinib (ROS1 inhibitor). This year's ASCO Annual Meeting will be held in Chicago, USA from May 31 to June 4, 2024, local time.
Dr. Zhou Hui, Senior Vice President of Cinda Biopharmaceutical GroupHe said, “We are very happy to announce the clinical data of many of Cinda Biotech's next-generation innovative oncology antibodies and ADC molecules for the first time at this ASCO conference. We are delighted with the results obtained in early exploration, and they also give us full confidence in further development. As one of the few biopharmaceutical companies with an “IO+ADC” technology platform and sufficient pipeline reserves, Cinda Biotech will continue to make breakthroughs in the field of cancer treatment and is committed to providing doctors and patients with more innovative, effective and safe treatment methods and solutions.”
Summary information on key clinical findings is as follows:
Summary title | summary | Conference types and presentation formats | showtimes (US Central Time) | speakers |
IBI363 (PD-1/IL-2 bispecific antibody fusion protein) | ||||
The world's first (first-in-class) PD-1/IL-2 bispecific antibody fusion protein IBI363 in the evening | 3593 | Poster Session - Gastrointestinal Tumors - Colorectal and anal cancer | June 1, 2024 1:30-4:30 p.m. | Professor Chen Yiwen |
The world's first (first-in-class) PD-1/IL-2 bispecific antibody fusion protein IBI363 treatment | 9562 | Poster Session - Melanoma/Skin | June 1, 2024 1:30 p.m. - 4:30 p.m. | Professor Chen Yu |
PD-1/IL-2 bispecific antibody fusion protein IBI363 treats patients with other solid tumors: Preliminary safety and efficacy results from the Phase I study | e14593 | Online publication | May 23, 2024 5:00 p.m. (*US Eastern Time) | Professor Shirley Bai |
IBI389 (Anti-CLDN18.2/CD3 bispecific antibodies) | ||||
Anti-CLDN18.2/CD3 bispecific antibody IBI389 in patients with solid tumors and gastric or gastroesophageal tumors | 2519 | Quick Oral Report - Developmental Governance | June 2, 2024 11:30 a.m. - 1:00 p.m. | Professor Zheng Li |
Safety of the anti-CLDN18.2/CD3 bispecific antibody IBI389 in patients with advanced pancreatic duct adenocarcinoma | 4011 | Oral Report (Clinical Science Discussion) | June 2, 2024 4:30 p.m. - 6:00 p.m. | Professor Hao Jihui |
IBI343 (Anti-CLDN18.2 ADC) | ||||
Safety of IBI343 (anti-Claudin18.2 ADC) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer | 3037 | Poster Session - Treatment Development - Session | June 1, 2024 9:00-12:00 a.m. | Professor Yu Xianping |
IBI310 (Anti-CTLA-4antibody) | ||||
IBI310 (anti-CTLA-4 antibody) combined with cindilizumab (anti-PD-1 antibody) against microsatellites | 3505 | Oral Presentation - Gastrointestinal Tumors - Knots | June 2, 2024 8:00 a.m. - 11:00 a.m. | Professor Xu Ruihua |
taretinib (ROS1inhibitors) | ||||
Efficacy and safety of tarretinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer: | 8520 | Quick Oral Report - Lung Cancer - Advanced | June 1, 2024 4:30-6:00 p.m. | Professor Li Wei |
IBI110 (Anti-LAG-3antibody) | ||||
Treatment of advanced alveoli with IBI110 (anti-LAG-3 antibody) combined with cindilimab (anti-PD-1 antibody) | 11559 | Poster Session - Sarcoma | June 1, 2024 1:30-4:30 p.m. | Professor Liu Jiayong |
Dabershu(Cindilizumab)[1] | ||||
Efficacy and safety of cindilizumab combined with paclitaxel and cisplatin in the neoadjuvant treatment of advanced cervical cancer: | 5512 | Quick Oral Report - Gynecologic Oncology | June 1, 2024 8:00-9:30 a.m. | Professor Liu Jihong |
Oral robotic surgery to treat HPV after neo-adjuvant cindirizumab combined with platinum-containing dual-agent chemotherapy | 6011 | Oral Report (Clinical Science Discussion) | June 3, 2024 3:00-4:00 p.m. | Professor Song Ming |
Single arm phase 2 study: cindilimab combined with doxorubicin and ifosfamide (AI) as advanced | 11505 | Oral Report - Sarcoma | June 3, 2024 3:00-6:00 p.m. | Professor Luo Zhiguo |
BBCAPX-II study survival results update: cindirizumab combined with bevacizumab and CapeOx 1 | 3563 | Poster Session - Gastrointestinal Tumors - Colorectal and anal cancer | June 1, 2024 1:30-4:30 p.m. | Professor Yuan Ying |
advanced or metastatic gastroesophageal conjunctions with cindilizumab combined with albumin and paclitaxel second-line treatment | 4037 | Poster Session - Gastrointestinal Tumors - | June 1, 2024 1:30-4:30 p.m. | Professor Jiang Zhichao |
Cindilizumab plus axitinib for advanced FH-deficient renal cell carcinoma: a multi-center, open | 4523 | Poster Session - Department of Urogenital Medicine | June 2, 2024 9:00-12:00 a.m. | Professor Zeng Hao |
First-line treatment of advanced non-clear cell kidney cancer (nCCRR) with cindilizumab plus anlotinib: 1 | 4544 | Poster Session - Department of Urogenital Medicine | June 2, 2024 9:00-12:00 a.m. | Professor Dong Pei |
Cindilizumab combined with fruquintinib in the treatment of advanced pMMR endometrial cancer: a multi-case study | 5619 | Poster Session - Gynecologic Oncology | June 3, 2024 9:00-12:00 a.m. | Professor Wu Xiaohua |
New adjuvant of cindilimab combined with chemotherapy (2 cycles vs. 3 cycles) to treat treatable non-small cell lung cancer Marker analysis results | 8048 | Poster Session - Lung Tumors - Non | June 3, 2024 1:30-4:30 p.m. | Professor Qiu Fuming |
Nelec(olevatinib) | ||||
Orebatinib (HQP1351) treats tyrosine kinase inhibitor (TKI) -resistant succinic acid prolapse | 11502 | Oral Report - Sarcoma | June 3, 2024 3:00-6:00 p.m. | Professor Qiu Haibo |
About Cinda Biotech
The mission and goal of Cinda Biotech is to develop high-quality biopharmaceuticals that ordinary people can afford to use. Founded in 2011, Cinda Biotech is committed to developing, producing and selling innovative drugs for major diseases such as oncology, autoimmunity, metabolism, and ophthalmology, so that our work can benefit more lives. The company has been approved for listing 10 products. They are cindilizumab injections (dabershu), bevacizumab injection (Dayoutong), adalimumab injection (Sulixin), rituximab injection (dabervac), pemitinib tablets (dabartan), orebatinib tablets (Nelik), remocizumab injection (Shiranze)2, ceptinib capsules (retinoid)2, igiorense injection (fukosu)) and tolecizumab injections (Cimpiroc). Currently, there are also 3 varieties in the NMPA review. 5 new drug molecules have entered phase III or key clinical research, and 18 new drug types have entered clinical research.
The company has reached more than 30 strategic partnerships with international partners such as Eli Lilly, Roche, Sanofi, Adimab, Incyte, and MD Anderson Cancer Center. While continuously developing innovative drugs and seeking its own development, Cinda Biotech adheres to the people-centered development philosophy of economic construction. Over the years, we have always been scientific and kind, adhering to the “patient-centered” approach, caring for patients and their families, and actively fulfilling social responsibilities. The company has successively initiated and participated in a number of drug charity aid projects, so that more and more patients can benefit from advances in life science and can buy and use high-quality biopharmaceuticals. By the end of 2023, the Cinda Biotech Patient Assistance Program had benefited more than 170,000 ordinary patients, with a total drug donation value of RMB 3.4 billion. Cinda Biotech hopes to work with everyone to raise the level of development of China's biopharmaceutical industry to meet people's accessibility to medicine and people's pursuit of a better life and health.
For more information, please visit the company website:.
Declarations:1. Cinda Biotech does not recommend the use of unapproved drugs/indications. |
2. Remocizumab injection (Shiranzou) and ceptinib capsules (retinoid) Developed by Eli Lilly |
Forward-looking statements
The information published in this press release may include certain forward-looking statements. These statements are inherently risky and uncertain. When using “anticipate”, “believe”, “anticipate”, “expect”, “intention” and other similar terms, the purpose of any statement relating to the Company is to indicate that it is a forward-looking statement. The Company is under no obligation to update these predictive statements on an ongoing basis.
These forward-looking statements are based on the Company's management's existing views, assumptions, expectations, estimates, predictions and understandings of future affairs at the time the statements are made. These statements are not a guarantee of future development and are affected by risks, uncertainties and other factors. Some are beyond the Company's control and are difficult to predict. As a result, actual results may differ significantly from the information contained in forward-looking statements due to future changes and developments in our business, competitive environment, and political, economic, legal and social conditions.
[1] With the exception of abstract 5619, all parts of cindilizumab are clinical studies (IIT) initiated based on investigator applications |